Brodalumab: A new way to inhibit IL ‐17 in psoriasis

Dermatologic TherapyVolume 33, Issue 3 e13403 Review Article Brodalumab: A new way to inhibit IL-17 in psoriasis Paola Facheris, Corresponding Author Paola Facheris paola.facheris91@gmail.com orcid.org/0000-0002-5171-9854 Dermatology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy Correspondence Paola Facheris, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. Email: paola.facheris91@gmail.comSearch for more papers by this authorMario Valenti, Mario Valenti Dermatology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ItalySearch for more papers by this authorGiulia Pavia, Giulia Pavia Dermatology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ItalySearch for more papers by this authorElena Guanziroli, Elena Guanziroli Dermatology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, ItalySearch for more papers by this authorAlessandra Narcisi, Alessandra Narcisi Dermatology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, ItalySearch for more papers by this authorRiccardo G. Borroni, Riccardo G. Borroni Dermatology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ItalySearch for more papers by this authorAntonio Costanzo, Antonio Costanzo Dermatology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ItalySearch for more papers by this author Paola Facheris, Corresponding Author Paola Facheris paola.facheris91@gmail.com orcid.org/0000-0002-5171-9854 Dermatology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy Correspondence Paola Facheris, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. Email: paola.facheris91@gmail.comSearch for more papers by this authorMario Valenti, Mario Valenti Dermatology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ItalySearch for more papers by this authorGiulia Pavia, Giulia Pavia Dermatology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ItalySearch for more papers by this authorElena Guanziroli, Elena Guanziroli Dermatology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, ItalySearch for more papers by this authorAlessandra Narcisi, Alessandra Narcisi Dermatology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, ItalySearch for more papers by this authorRiccardo G. Borroni, Riccardo G. Borroni Dermatology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ItalySearch for more papers by this authorAntonio Costanzo, Antonio Costanzo Dermatology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ItalySearch for more papers by this author First published: 13 April 2020 https://doi.org/10.1111/dth.13403Citations: 13 Paola Facheris, Mario Valenti, and Giulia Pavia should be considered joint first authors. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract Psoriasis is a chronic inflammatory disease that affects 2% to 4% of the population; about 20% of the patients present a moderate-to-severe form. The IL-23/Th17/IL-17 molecular axis is considered crucial in the pathogenesis of psoriasis and IL-17 is fundamental in the maintenance of the immune and inflammatory alterations causing psoriasis. Expression of IL-17A, IL-17F, and IL-17C is strongly increased in psoriatic plaques. Effective therapy leads to restoration of the expression of a wide range of genes (including effector cytokines and chemokines downstream of IL-17) to near normal levels. Brodalumab is the first biologic drug targeting specifically the subunit A of the IL-17 receptor (IL-17RA) and thus inhibiting not only IL-17A but also other members of the IL-17 family. Brodalumab is very effective and safe in treating moderate-to severe psoriasis. CONFLICT OF INTEREST The authors declare no potential conflict of interest. Citing Literature Volume33, Issue3May/June 2020e13403 RelatedInformation